Riely, Gregory James

Publications

Sort by

Co-Author Network

selected publications

Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial. JAMA oncology. 2020 Academic Article GET IT
Times cited: 80
COVID-19 in patients with lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2020 Academic Article GET IT
Times cited: 152
Pan-Cancer Efficacy of Vemurafenib in BRAF ^V600-Mutant Non-Melanoma Cancers. Cancer discovery. 2020 Academic Article GET IT
Times cited: 65
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nature medicine. 2020 Academic Article GET IT
Times cited: 201
Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Comment GET IT
Times cited: 169
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review. JAMA. 2019 Review GET IT
Times cited: 584
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Academic Article GET IT
Times cited: 207
Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Academic Article GET IT
Times cited: 171
A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. Journal of the National Cancer Institute. 2019 Academic Article GET IT
Times cited: 79
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Academic Article GET IT
Times cited: 193
Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers. Cold Spring Harbor molecular case studies. 2019 Academic Article GET IT
Times cited: 16
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 608
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 200
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018 Academic Article GET IT
Times cited: 99
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 300
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018 Academic Article GET IT
Times cited: 55
YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proceedings of the National Academy of Sciences of the United States of America. 2018 Academic Article GET IT
Times cited: 35
Improving therapy for patients with epidermal growth factor receptor-mutant lung cancer. Cancer. 2018 Editorial Article GET IT
Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers. Cancer discovery. 2018 Academic Article GET IT
Times cited: 114
Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 164
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 882
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 236
Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients. Journal of oncology practice. 2017 Comment GET IT
Times cited: 3
Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases. Cancer. 2017 Academic Article GET IT
Times cited: 22
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 454
Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors. PloS one. 2017 Academic Article GET IT
Times cited: 42
An approach to suppress the evolution of resistance in BRAF^V600E-mutant cancer. Nature medicine. 2017 Academic Article GET IT
Times cited: 107
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature medicine. 2017 Academic Article GET IT
Times cited: 1922
Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. 2017 GET IT
Times cited: 883
Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib. Lung cancer (Amsterdam, Netherlands). 2017 Academic Article GET IT
Times cited: 34
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer discovery. 2017 Academic Article GET IT
Times cited: 399
Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer. Clinical pharmacology and therapeutics. 2017 Review GET IT
Times cited: 15
Investigation of patterns of nodal metastases in BRAF mutant lung cancer. Lung cancer (Amsterdam, Netherlands). 2017 Academic Article GET IT
Times cited: 6
Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. Hematology/oncology clinics of North America. 2017 Review GET IT
Times cited: 23
Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 36
Targeting ALK: Precision Medicine Takes on Drug Resistance. Cancer discovery. 2017 Review GET IT
Times cited: 348
Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer-Incidence, radiological features and clinical characteristics. Lung cancer (Amsterdam, Netherlands). 2017 Academic Article GET IT
Times cited: 16
Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 58
Radiogenomic evaluation of lung cancer - Are there imaging characteristics associated with lung adenocarcinomas harboring BRAF mutations?. Clinical imaging. 2016 Academic Article GET IT
Times cited: 14
Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Review GET IT
Times cited: 89
Thymic Carcinoma Management Patterns among International Thymic Malignancy Interest Group (ITMIG) Physicians with Consensus from the Thymic Carcinoma Working Group. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Academic Article GET IT
Times cited: 16
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. The Lancet. Oncology. 2016 Academic Article GET IT
Times cited: 331
Clinical Application of Picodroplet Digital PCR Technology for Rapid Detection of EGFR T790M in Next-Generation Sequencing Libraries and DNA from Limited Tumor Samples. The Journal of molecular diagnostics : JMD. 2016 Academic Article GET IT
Times cited: 18
A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Academic Article GET IT
Times cited: 30
Clinician Perspectives on Current Issues in Lung Cancer Drug Development. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Review GET IT
Times cited: 5
NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. 2016 GET IT
Times cited: 68
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. The Lancet. Oncology. 2016 Academic Article GET IT
Times cited: 325
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Academic Article GET IT
Times cited: 81
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. The Lancet. Oncology. 2016 Academic Article GET IT
Times cited: 396
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. Journal of the National Comprehensive Cancer Network : JNCCN. 2016 Academic Article GET IT
Times cited: 331
Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. Clinical lung cancer. 2016 Academic Article GET IT
Times cited: 100
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. The Lancet. Oncology. 2015 Academic Article GET IT
Times cited: 555
A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer. 2015 GET IT
Times cited: 126
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 303
Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib. Cancer. 2015 Academic Article GET IT
Times cited: 156
EGFR: The Paradigm of an Oncogene-Driven Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 66
Non-Small Cell Lung Cancer, Version 6.2015. 2015 GET IT
Times cited: 320
Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 86
Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas. Cancer. 2015 Academic Article GET IT
Times cited: 14
Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Academic Article GET IT
Times cited: 87
Massively parallel sequencing identifies recurrent mutations in TP53 in thymic carcinoma associated with poor prognosis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Academic Article GET IT
Times cited: 43
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 529
Beyond "second-line" in non-small cell lung cancer: therapy and supportive care. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2015 Review GET IT
Times cited: 2
Clinical characteristics and outcomes for patients with thymic carcinoma: evaluation of Masaoka staging. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Academic Article GET IT
Times cited: 44
Non-small cell lung cancer, version 1.2015. Journal of the National Comprehensive Cancer Network : JNCCN. 2014 Academic Article GET IT
Times cited: 144
Clinical characteristics and course of 63 patients with BRAF mutant lung cancers. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Academic Article GET IT
Times cited: 97
Emerging science and therapies in non-small-cell lung cancer: targeting the MET pathway. Clinical lung cancer. 2014 Academic Article GET IT
Times cited: 3
Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Review GET IT
Times cited: 73
Crizotinib in ROS1-rearranged non-small-cell lung cancer. The New England journal of medicine. 2014 Academic Article GET IT
Times cited: 1470
Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements?. Lung cancer (Amsterdam, Netherlands). 2014 Academic Article GET IT
Times cited: 54
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. The Lancet. Oncology. 2014 Academic Article GET IT
Times cited: 612
Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. Lung cancer (Amsterdam, Netherlands). 2014 Academic Article GET IT
Times cited: 44
Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation. The American journal of surgical pathology. 2014 Academic Article GET IT
Times cited: 118
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer discovery. 2014 Academic Article GET IT
Times cited: 326
Small-cell lung cancers in patients who never smoked cigarettes. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Academic Article GET IT
Times cited: 89
Can IASLC/ATS/ERS subtype help predict response to chemotherapy in small biopsies of advanced lung adenocarcinoma?. The European respiratory journal. 2014 Editorial Article GET IT
Times cited: 7
Germline EGFR T790M mutation found in multiple members of a familial cohort. 2014 GET IT
Times cited: 50
Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease. The American journal of surgical pathology. 2014 Academic Article GET IT
Times cited: 182
Ceritinib in ALK-rearranged non-small-cell lung cancer. The New England journal of medicine. 2014 Academic Article GET IT
Times cited: 1075
Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma. International journal of radiation oncology, biology, physics. 2014 Academic Article GET IT
Times cited: 82
Failure patterns relative to radiation treatment fields for stage II-IV thymoma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Academic Article GET IT
Times cited: 35
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Academic Article GET IT
Times cited: 211
Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Academic Article GET IT
Times cited: 161
[Chemotherapy definitions and policies for thymic malignancies]. 2014 GET IT
Times cited: 1
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. The Lancet. Oncology. 2014 Academic Article GET IT
Times cited: 98
Unsuspected collision of synchronous lung adenocarcinomas: a potential cause of aberrant driver mutation profiles. 2014 GET IT
Times cited: 6
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Science translational medicine. 2013 Academic Article GET IT
Times cited: 389
Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 Academic Article GET IT
Times cited: 100
The impact of cigarette smoking on the frequency of and qualitative differences in KRAS mutations in Korean patients with lung adenocarcinoma. Yonsei medical journal. 2013 Academic Article GET IT
Times cited: 18
Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab. Cancer chemotherapy and pharmacology. 2013 Academic Article GET IT
Times cited: 11
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. The New England journal of medicine. 2013 Academic Article GET IT
Times cited: 2900
Non-small cell lung cancer, version 2.2013. 2013 GET IT
Times cited: 356
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 468
Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology. 2013 GET IT
Times cited: 56
KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2013 Academic Article GET IT
Times cited: 91
Characteristics of lung cancers harboring NRAS mutations. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 116
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 1891
Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 Academic Article GET IT
Times cited: 267
New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Review GET IT
Times cited: 399
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. Journal of the National Comprehensive Cancer Network : JNCCN. 2013 Academic Article GET IT
Times cited: 55
Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 Academic Article GET IT
Times cited: 25
Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2012 Academic Article GET IT
Times cited: 148
Non-small cell lung cancer. 2012 GET IT
Times cited: 320
Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 444
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer discovery. 2012 Academic Article GET IT
Times cited: 582
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. The Lancet. Oncology. 2012 Academic Article GET IT
Times cited: 1085
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2012 Academic Article GET IT
Times cited: 109
Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Cancer. 2012 Academic Article GET IT
Times cited: 117
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proceedings of the National Academy of Sciences of the United States of America. 2012 Academic Article GET IT
Times cited: 381
Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. Cancer. 2012 Academic Article GET IT
Times cited: 46
Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2012 Academic Article GET IT
Times cited: 34
A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2012 Academic Article GET IT
Times cited: 132
ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma. 2012 GET IT
Times cited: 38
Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 132
Malignant pleural mesothelioma. 2012 GET IT
Times cited: 35
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Molecular cancer therapeutics. 2011 Academic Article GET IT
Times cited: 176
Management and outcomes of relapse after treatment for thymoma and thymic carcinoma. The Annals of thoracic surgery. 2011 Academic Article GET IT
Times cited: 38
Poly adenosine diphosphate-ribose polymerase inhibitors and heat shock protein 90 inhibitors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 Academic Article GET IT
Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 Academic Article GET IT
Times cited: 106
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. The Lancet. Oncology. 2011 Academic Article GET IT
Times cited: 792
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proceedings of the American Thoracic Society. 2011 Conference Paper GET IT
Times cited: 430
Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 356
Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 56
A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 Academic Article GET IT
Times cited: 114
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. The European respiratory journal. 2011 Academic Article GET IT
Times cited: 74
Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 124
Chemotherapy definitions and policies for thymic malignancies. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 Academic Article GET IT
Times cited: 77
Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 Academic Article GET IT
Times cited: 63
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 561
Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 231
A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion. Cancer chemotherapy and pharmacology. 2011 Academic Article GET IT
Times cited: 24
Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 Academic Article GET IT
Times cited: 217
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 Review GET IT
Times cited: 3657
Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2011 Academic Article GET IT
Times cited: 782
Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 118
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 510
Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 Academic Article GET IT
Times cited: 110
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 531
Thymic malignancies. 2010 GET IT
Times cited: 13
Induction therapy for locally advanced thymoma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010 Review GET IT
Times cited: 38
Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010 Academic Article GET IT
Times cited: 78
Insulin-like growth factor-1 receptor expression in thymic malignancies. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010 Academic Article GET IT
Times cited: 42
Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010 Academic Article GET IT
Times cited: 72
Non-small cell lung cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2010 Review GET IT
Times cited: 538
Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. Cancer. 2010 Academic Article GET IT
Times cited: 103
Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 72
Lung cancer in 'Never-smokers': molecular factors trump risk factors. Oncology (Williston Park, N.Y.). 2010 Comment GET IT
Times cited: 3
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 699
Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 152
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 356
Comparison of patterns of relapse in thymic carcinoma and thymoma. The Journal of thoracic and cardiovascular surgery. 2009 Academic Article GET IT
Times cited: 102
Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. Radiology. 2009 Academic Article GET IT
Times cited: 261
KRAS mutations in non-small cell lung cancer. Proceedings of the American Thoracic Society. 2009 Review GET IT
Times cited: 466
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 42
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. 2008 GET IT
Times cited: 247
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 160
KRAS mutational testing in the selection of patients for EGFR-targeted therapies. Seminars in diagnostic pathology. 2008 Review GET IT
Times cited: 15
KRAS mutations: an old oncogene becomes a new predictive biomarker. The Journal of molecular diagnostics : JMD. 2008 Academic Article GET IT
Times cited: 47
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 467
Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. The American journal of surgical pathology. 2008 Academic Article GET IT
Times cited: 345
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2008 Review GET IT
Times cited: 71
Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2008 Article GET IT
Times cited: 9
The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations. Lung cancer (Amsterdam, Netherlands). 2008 Review GET IT
Times cited: 17
EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. The Journal of molecular diagnostics : JMD. 2008 Academic Article GET IT
Times cited: 166
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 283
Multimodality therapy for locally advanced thymomas: state of the art or investigational therapy?. The Annals of thoracic surgery. 2008 Editorial Article GET IT
Times cited: 19
Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 104
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proceedings of the National Academy of Sciences of the United States of America. 2007 Academic Article GET IT
Times cited: 1479
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 266
Novel agents in the treatment of lung cancer: Fourth Cambridge Conference. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Conference Paper GET IT
Times cited: 7
Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer. 2007 Academic Article GET IT
Times cited: 93
Vascular endothelial growth factor trap in non small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Review GET IT
Times cited: 64
Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Review GET IT
Times cited: 326
A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy. Lung cancer (Amsterdam, Netherlands). 2006 Academic Article GET IT
Times cited: 63
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 726
Molecular on/off switch. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 10
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 199
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 657
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. 2005 GET IT
Times cited: 3130
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS medicine. 2005 Academic Article GET IT
Times cited: 1383
Negative regulation of T cell activation by placental protein 14 is mediated by the tyrosine phosphatase receptor CD45. The Journal of biological chemistry. 2003 Academic Article GET IT
Times cited: 44
Focal localization of placental protein 14 toward sites of TCR engagement. Journal of immunology (Baltimore, Md. : 1950). 2002 Academic Article GET IT
Times cited: 15
A rheostatic mechanism for T-cell inhibition based on elevation of activation thresholds. Blood. 2001 Academic Article GET IT
Times cited: 34
alpha2-macroglobulin modulates the immunoregulatory function of the lipocalin placental protein 14. The Biochemical journal. 2000 Academic Article GET IT
Times cited: 12
Placental protein 14 functions as a direct T-cell inhibitor. Cellular immunology. 1999 Academic Article GET IT
Times cited: 81
Isolation and characterization of a TATA-less promoter for the human beta 3 integrin gene. Blood. 1994 Academic Article GET IT
Times cited: 67

more ...

less ...

Background

education and training

M.D., Case Western Reserve University School of Medicine 2001
Ph.D., Case Western Reserve University 1999
B.A., The Johns Hopkins University 1994

Contact

full name

Gregory James Riely

VIVO Weill Cornell Medical College

Gregory James Riely Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name